Importantly, it was then demonstrated that co-targeting of PI3K and ERBB3 could be an effective approach circumventing this ERBB3 feedback, thus resulting in good antitumor efficacy for HPV(+) HNSCC [74,75]. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.